[go: up one dir, main page]

MY208876A - Trispecific binding proteins, methods, and uses thereof - Google Patents

Trispecific binding proteins, methods, and uses thereof

Info

Publication number
MY208876A
MY208876A MYPI2021005932A MYPI2021005932A MY208876A MY 208876 A MY208876 A MY 208876A MY PI2021005932 A MYPI2021005932 A MY PI2021005932A MY PI2021005932 A MYPI2021005932 A MY PI2021005932A MY 208876 A MY208876 A MY 208876A
Authority
MY
Malaysia
Prior art keywords
binding
binding proteins
polypeptide
binds
proteins
Prior art date
Application number
MYPI2021005932A
Inventor
Cendrine Lemoine
Batrice Cameron
Tarik Dabdoubi
Catherine Prades
Ling Xu
Zhen Xing
Lan Wu
Ronnie Wei
Edward Seung
Joerg Regula
Huawei Qiu
Gary J Nabel
Joerg Birkenfeld
Zhi-Yong Yang
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MY208876A publication Critical patent/MY208876A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)

Abstract

Provided herein are trispecific and/or tri valent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CDS polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
MYPI2021005932A 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof MY208876A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831572P 2019-04-09 2019-04-09
EP19306261 2019-10-02
PCT/US2020/027320 WO2020210392A1 (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Publications (1)

Publication Number Publication Date
MY208876A true MY208876A (en) 2025-06-05

Family

ID=72751423

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021005932A MY208876A (en) 2019-04-09 2020-04-08 Trispecific binding proteins, methods, and uses thereof

Country Status (15)

Country Link
EP (1) EP3953388A1 (en)
JP (2) JP7664175B2 (en)
KR (1) KR20210149141A (en)
CN (1) CN113950484B (en)
AU (1) AU2020272839A1 (en)
BR (1) BR112021019915A2 (en)
CA (1) CA3136821A1 (en)
CO (1) CO2021014918A2 (en)
IL (1) IL286929A (en)
MX (1) MX2021012386A (en)
MY (1) MY208876A (en)
PH (1) PH12021500041A1 (en)
SG (1) SG11202111012QA (en)
TW (1) TW202104261A (en)
WO (1) WO2020210392A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103478RA (en) * 2018-10-09 2021-05-28 Sanofi Sa Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
TW202104274A (en) * 2019-04-09 2021-02-01 法商賽諾菲公司 Trispecific and/or trivalent binding proteins for treatment of hiv infection
WO2022190579A1 (en) 2021-03-09 2022-09-15 有限会社沖田工業技術開発 Linear material manufacturing method and linear material manufacturing device
KR20250075711A (en) * 2022-10-06 2025-05-28 비카라 테라퓨틱스 인크. Multispecific proteins and related methods
WO2025027003A1 (en) 2023-07-31 2025-02-06 Sanofi Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas
WO2025209593A1 (en) * 2024-04-06 2025-10-09 华深智药生物科技(苏州)有限公司 Multi-specific antibody t cell engager
WO2025238419A1 (en) * 2024-05-17 2025-11-20 Sanofi Methods of treating cancer using trispecific binding proteins targeting her2-expressing tumors
WO2025245150A1 (en) * 2024-05-20 2025-11-27 The Trustees Of Columbia University In The City Of New York Anti-pd-1 x il-25 bispecific antibody to treat cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
TWI743461B (en) * 2011-03-28 2021-10-21 法商賽諾菲公司 Dual variable region antibody-like binding proteins having cross-over binding region orientation
ES2808914T3 (en) * 2014-09-04 2021-03-02 Stemcell Tech Inc Soluble antibody complexes for the activation and expansion of T lymphocytes or NK cells
CA2968162A1 (en) * 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
DK3221356T3 (en) * 2014-11-20 2020-11-02 Hoffmann La Roche T cell activating bispecific antigen binding molecules against folr1 and cd3
CN114230667A (en) * 2015-01-23 2022-03-25 赛诺菲 anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123
AU2016280159A1 (en) * 2015-06-17 2017-12-07 Genentech, Inc. Anti-HER2 antibodies and methods of use
WO2016209956A1 (en) * 2015-06-26 2016-12-29 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
EP3365366B1 (en) * 2015-10-25 2021-07-14 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
JP7195929B2 (en) * 2016-04-13 2022-12-26 サノフイ Trispecific and/or trivalent binding proteins
CA3030841A1 (en) * 2016-07-14 2018-01-18 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
EP3575319A4 (en) * 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. Bifunctional molecule and use thereof
CA3078800A1 (en) * 2017-10-10 2019-04-18 Sanofi Anti-cd38 antibodies and methods of use
SG11202103478RA (en) * 2018-10-09 2021-05-28 Sanofi Sa Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection

Also Published As

Publication number Publication date
JP2022527994A (en) 2022-06-07
CA3136821A1 (en) 2020-10-15
TW202104261A (en) 2021-02-01
SG11202111012QA (en) 2021-11-29
MX2021012386A (en) 2022-01-18
IL286929A (en) 2021-10-31
JP2025063225A (en) 2025-04-15
EP3953388A1 (en) 2022-02-16
WO2020210392A1 (en) 2020-10-15
CN113950484B (en) 2025-07-29
KR20210149141A (en) 2021-12-08
BR112021019915A2 (en) 2021-12-07
AU2020272839A1 (en) 2021-12-02
PH12021500041A1 (en) 2022-06-06
CN113950484A (en) 2022-01-18
CO2021014918A2 (en) 2021-11-19
JP7664175B2 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
MY208876A (en) Trispecific binding proteins, methods, and uses thereof
PH12018502182A1 (en) Trispecific and/or trivalent binding proteins
WO2017074878A8 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EP4442709A3 (en) Improved serum albumin binders
MX2024008521A (en) Improved serum albumin binders.
HRP20210041T1 (en) COVALENTLY BONDED DIATIELS HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND PROCEDURES FOR THEIR USE
PH12013502024A1 (en) Dual variable region antibody-like binding proteins having cross-over binding region orientation
EA202090718A1 (en) PROTEINS BINDING NKG2D, CD16 AND LECTIN-LIKE C-TYPE MOLECULE-1 (CLL-1)
MX2023003630A (en) Improved serum albumin binding immunoglobulin single variable domains.
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MY205342A (en) Bispecific 2+1 contorsbodies
WO2016130898A3 (en) Antibody therapeutics that bind ctla4
WO2017053469A3 (en) Cd3 binding polypeptides
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
MX2023004804A (en) Trispecific and/or trivalent binding proteins.
PH12022551231A1 (en) Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
PH12021500042A1 (en) Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection
EP4269433A3 (en) Tgf-beta-rii binding proteins
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EA202191078A3 (en) TRISSPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION
NZ748144B2 (en) Trispecific and/or trivalent binding proteins
ATE492564T1 (en) EPHB4-BINDING ANTIBODIES FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
NZ769355B2 (en) Anti-cd24 compositions and uses thereof
WO2023038803A3 (en) Engineered anti-her2 bispecific proteins
NZ769355A (en) Anti-cd24 compositions and uses thereof